NCT02492217View on ClinicalTrials.gov

Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 28, 2018

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Adalimumab

Trial Locations (1)

Unknown

Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon

All Listed Sponsors
lead

Universidade Nova de Lisboa

OTHER

NCT02492217 - Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients | Biotech Hunter | Biotech Hunter